Synapse - Works

Results (5712)

Modulation of RNA splicing enhances response to BCL2 inhibition in acute myeloid leukemia

Meeting Abstract

Wang, E.; Pineda, J. M. B.; Bourcier, J.; Stahl, M.; Penson, A. V.; Wakiro, I.; Singer, M. E.; Cui, D.; Erickson, C.; Knorr, K.; more...
Blood (2021)

Fulltext@MSK | Save

ERK2 substrate binding domains perform opposing roles in pathogenesis of a JAK2V617F-driven myeloproliferative neoplasm

Meeting Abstract

Truong, B.; Zhang, Y.; Fahl, S.; Qcai, K.; Martinez, E.; Al-Saleem, E.; Gong, Y.; Liebermann, D.; Soboloff, J.; Dunbrack, R.; more...
Blood (2021)

Fulltext@MSK | Save

Real-world management of patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens: Results from the AML Real World Evidence (ARC) Initiative

Meeting Abstract

Vachhani, P.; Wolach, O.; Garcia, J. S.; Zeidner, J. F.; Talati, C.; Pollyea, D. A.; Lai, C.; Moshe, Y.; Abedin, S.; Lavie, D.; more...
Blood (2021)

Fulltext@MSK | Save

Pharmacodynamic analysis of CAR-T cell persistence in patients with hematologic malignancies treated with NKTR-255, an IL-15 receptor agonist that enhances CD8 (+) T-cells: Preliminary results from a phase 1 study

Meeting Abstract

Turtle, C. J.; Budde, E.; Patel, K. K.; Perales, M. A.; Cowan, A. J.; Saeed, H.; Chavez, J. C.; Hirayama, A. V.; Kirchmeier, D. R.; Janakiram, M.; more...
Blood (2021)

Fulltext@MSK | Save

Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study

Meeting Abstract

Trudel, S.; Cohen, A. D.; Krishnan, A. Y.; Fonseca, R.; Spencer, A.; Berdeja, J. G.; Lesokhin, A.; Forsberg, P. A.; Laubach, J. P.; Costa, L. J.; more...
Blood (2021)

Fulltext@MSK | Save

Gilteritinib (GILT) monotherapy with addition of decitabine (DEC) in non-responders in older newly diagnosed (ND) FLT3 mutated acute myeloid leukemia (AML) patients having high and low variant allele frequency (VAF): A phase 2/1b sub-study of the Beat AML Master Trial

Meeting Abstract

Traer, E.; Huang, Y.; Mims, A. S.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; Schiller, G. J.; more...
Blood (2021)

Fulltext@MSK | Save

Prevalence of smoldering multiple myeloma: Results from the Iceland screens, treats, or prevents multiple myeloma (iStopMM) study

Meeting Abstract

Thorsteinsdottir, S.; Gislason, G. K.; Aspelund, T.; Rögnvaldsson, S.; Oskarsson, J. T. T.; Petirsdottir, I.; Sigurdsson, J. K.; Sigurdardottir, G. A.; Thordardottir, A. R.; Vidarsson, B.; more...
Blood (2021)

Fulltext@MSK | Save

Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: A multicenter observational study

Meeting Abstract

Tomas, A. A.; Fein, J. A.; Fried, S.; Fingrut, W.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; Lin, R. J.; Scordo, M.; more...
Blood (2021)

Fulltext@MSK | Save

Outcomes of chronic lymphocytic leukemia and Richter Transformation following discontinuation of noncovalent Bruton's Tyrosine Kinase inhibitors

Meeting Abstract

Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Pagel, J. M.; Jensen, J. L.; Battiato, K. E.; Fox, Y.; Meyer, K.; Bailey, N.; Rhodes, J. M.; more...
Blood (2021)

Fulltext@MSK | Save

Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax

Meeting Abstract

Thompson, M. C.; Roeker, L. E.; Coombs, C. C.; Jensen, J. L.; Kamdar, M.; Skarbnik, A.; Pagel, J. M.; Bailey, N.; Pu, J. J.; Jacobs, R.; more...
Blood (2021)

Fulltext@MSK | Save